ANXA3 and breast carcinoma: Further subgroup analyses revealed that the positive expression rate of ANXA3 in patients with triple-negative breast cancer (TNBC) (79.66%) was significantly higher than that in patients with other types of breast cancer (χ2 = 9.226; P = 0.026).